Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 9
Submit an article Journal homepage
169
Views
15
CrossRef citations to date
0
Altmetric
Letters to the Editor

Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab

Maria K. Angelopoulou Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSA
,
Gerassimos A. Pangalis Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSACorrespondence[email protected]
,
Sotirios Sachanas Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSA
,
Styliani I. Kokoris Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSA
,
Konstantinos Anargyrou Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSA
,
Zaharoula Galani Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSA
,
Christina Kalpadakis Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSA
&
Theodoros P. Vassilakopoulos Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, State University of New York at Buffalo, New YorkUSA
 show all
Pages 1817-1820 | Received 02 Jan 2008, Accepted 25 Apr 2008, Published online: 01 Jul 2009

References

  • Tallman M S, Peterson L C, Hakimian D, Gillis S, Polliack A. Treatment of hairy-cell leukemia: current views. Semin Hematol 1999; 36: 155–163
  • Tallman M S, Hakimian D, Rademaker A W, Zanzig C, Wollins E, Rose E, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow up of the Northwestern University experience. Blood 1996; 88: 1954–1959
  • Cheson B D. Immunologic and immunosuppressive complications of purine analogue therapy. J Clin Oncol 1995; 13: 2431–2448
  • Pangalis G A, Kyrtsonis M C, Vassilakopoulos T P, Dimopoulou M N, Siakantaris M P, Emmanouilides C, et al. Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. Curr Top Med Chem 2006; 6: 1657–1686
  • Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, et al. Efficacy of antiCD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046–1050
  • Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102: 810–813
  • Thomas D A, O'Brien S, Bueso-Ramos C, Faderl S, Keating M J, Giles F J, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906–3911
  • Foucar K, Catovsky D. Hairy cell leukemia. World Health Organization Classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, Lyon 2001; 138–141
  • Kalpadakis C, Pangalis G A, Dimopoulou M N, Vassilakopoulos T P, Kyrtsonis M-C, Korkolopoulou P, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25: 127–131
  • Buckstein R, Patel H, Chesney A, Reis M, Imrie K. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report. Hematology 2006; 11: 267–270
  • Ravandi F, Jorgensen J L, O'Brien S M, Verstovsek S, Koller C A, Faderl S, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107: 4658–4662
  • Else M, Osuji N, Forconi F, Dearden C, Del Giudice I, Matutes E, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110: 2240–2247
  • Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004; 73: 412–417
  • Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642
  • Sacchi S, Federico M, Vitolo U, Boccoinini C, Vallisa D, Baldini L, et al. Clinical activity and safety of combination immunotherapy with IFN-a2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951–958

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.